Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Large Drop in Short Interest

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the target of a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 145,548 shares, a drop of 34.7% from the July 30th total of 222,920 shares. Currently, 0.7% of the shares of the company are sold short. Based on an average daily trading volume, of 69,205 shares, the short-interest ratio is currently 2.1 days.

Analysts Set New Price Targets

Separately, BTIG Research assumed coverage on Serina Therapeutics in a report on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Serina Therapeutics currently has a consensus rating of “Buy” and an average target price of $8.00.

Serina Therapeutics Trading Up 3.3%

Serina Therapeutics stock traded up $0.08 during midday trading on Tuesday, reaching $2.50. 32,395 shares of the stock traded hands, compared to its average volume of 1,740,999. The firm has a market cap of $63.50 million, a PE ratio of -1.32 and a beta of 1.11. Serina Therapeutics has a 12-month low of $1.22 and a 12-month high of $5.83. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16. The company has a 50-day simple moving average of $2.25 and a two-hundred day simple moving average of $2.01.

Serina Therapeutics (NYSEAMERICAN:SER) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share (EPS) for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.